In this video made in observance of World Down Syndrome Day, a mother of a young son with Down syndrome describes why she supports cognitive research to develop drug therapies to address intellectual disabilities in Down syndrome.
In recent decades, improved health care, expanded education and community opportunities and the support of families and advocacy groups has improved quality of life for individuals with Down syndrome, and life expectancy has increased from 20 to 60+.
While progress over the last ten years certainly has been encouraging, there remains a large unmet medical need for drug therapies to address the learning challenges associated with Down syndrome, as well as the increased likelihood for Alzheimer’s disease.
Yet, remarkable progress in Down syndrome cognitive research has been made over a relatively short period of time. A clinical trial is underway to test a potential drug that improves neuro-transmission in a mouse model, and two other trials are underway.